Piramal Enterprises is currently trading at Rs. 2663.20, up by 6.40 points or 0.24% from its previous closing of Rs. 2656.80 on the BSE.
The scrip opened at Rs. 2684.00 and has touched a high and low of Rs. 2707.55 and Rs. 2655.35 respectively. So far 28354 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 3302.55 on 31-Aug-2018 and a 52 week low of Rs. 1796.75 on 26-Oct-2018.
Last one week high and low of the scrip stood at Rs. 2675.05 and Rs. 2372.15 respectively. The current market cap of the company is Rs. 49137.81 crore.
The promoters holding in the company stood at 49.99%, while Institutions and Non-Institutions held 31.76% and 18.25% respectively.
Piramal Enterprises’ partner for its global pharma businesses - Slate Run Pharmaceuticals LLC. (Slate Run) has launched generic cinacalcet hydrochloride tablets (30mg, 60mg and 90mg) in the United States (US).
Piramal’s subsidiary, Piramal Healthcare (UK) (PHL), has partnered with Slate Run Pharmaceuticals with the goal of developing a non-infringing formulation of cinacalcet hydrochloride tablets. Cinacalcet tablets are indicated for the treatment of secondary hyperthyroidism (HPT) in adult chronic kidney disease patients on dialysis and hypercalcemia in adult patients with parathyroid carcinoma.
Piramal Enterprises is one of India’s large diversified companies, with a presence in Pharmaceuticals, Healthcare Information Management and Financial Services.
| Company Name | CMP |
|---|---|
| Bajaj Finance | 955.05 |
| Shriram Finance | 1007.95 |
| Aditya Birla Capital | 363.05 |
| Chola Invest & Fin. | 1676.05 |
| Tata Capital | 321.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: